The WHO makes great sport of taking the pharmaceutical industry to task for its inability to provide everyone in the developing world with the drugs they need. This so-called market failure is being used at negotiations in Geneva this month to bring research and patents under official control, managed by the WHO.
But the WHO has trouble managing itself. Before it pushes on with this agenda, it should make sure it has strong evidence.
In fact, though, it lacks evidence for this -- and many more of its global recommendations.
In the May issue of The Lancet, researchers found that "WHO guidelines do not seem to be closely followed when [the] WHO develops recommendations for member states."
The editor of The Lancet told reporters that this "is a pretty seismic event ... it undermines the very purpose of [the] WHO."
The most sensitive indicator of broad health trends is the infant mortality rate. In September, UNICEF released new data showing that "the global rate for the under-five population fell from 20 million annually in 1960 to 9.7 million in 2006."
But The Lancet published in the same month an article showing "disappointing results in the reduction of child mortality worldwide" and concluded by asking "why should journals trust the research such agencies produce and why should anyone trust their health policies and initiatives?"
The WHO's new Draft Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (IGWG) aims to further weaken intellectual property and bring research and development under the control of governments and international bodies. It claims there are too few drugs for the "neglected" tropical diseases found in poor countries and that drug prices -- and the international patent system -- prevent the poor from getting what medicines do exist.
In fact, three of these "neglected" diseases are AIDS, tuberculosis and malaria. Since 2004, donors have spent an enormous US$41.8 billion on them.
Six tropical diseases, often considered "neglected," account for 0.3 percent of all global deaths -- and all of these diseases have multi-million-dollar research projects underway.
As for the alleged barrier of drug prices, numerous studies -- including the WHO's -- show that the most important barrier to the poor getting medicines is lack of medical staff and infrastructure to administer the drugs. And the biggest factor in the actual price paid by patients is local regulation, taxes and tariffs in poor countries.
So there is plenty of evidence, but the WHO is ignoring it.
Indeed, past evidence, from telephone monopolies to Chinese central planning, shows that nationalizing any business stifles innovation and, in the case of drugs, would hinder future efforts to create drugs for the poorest countries. This is particularly threatening, as drug-resistant strains of HIV/AIDS, malaria and tuberculosis become more prevalent in these regions.
The WHO wants to bring drug development under official control, replacing the commercial research and development, underpinned by intellectual property rights, that has proved so successful in so many fields. Not only will this treaty undermine innovation, it is supported by false premises and flies in the face of real evidence.
Taiwan, denied participation in the WHO, knows all too well how politics trumps evidence or sense in international organizations. Member states need to knock this treaty on the head at this month's meeting before the WHO does lasting damage to global health.
Jeremiah Norris is director of the Center for Science in Public Policy at the Hudson Institute, a policy think tank in Washington.
From the Iran war and nuclear weapons to tariffs and artificial intelligence, the agenda for this week’s Beijing summit between US President Donald Trump and Chinese President Xi Jinping (習近平) is packed. Xi would almost certainly bring up Taiwan, if only to demonstrate his inflexibility on the matter. However, no one needs to meet with Xi face-to-face to understand his stance. A visit to the National Museum of China in Beijing — in particular, the “Road to Rejuvenation” exhibition, which chronicles the rise and rule of the Chinese Communist Party — might be even more revealing. Xi took the members
A Pale View of Hills, a movie released last year, follows the story of a Japanese woman from Nagasaki who moved to Britain in the 1950s with her British husband and daughter from a previous marriage. The daughter was born at a time when memories of the US atomic bombing of Nagasaki during World War II and anxiety over the effects of nuclear radiation still haunted the community. It is a reflection on the legacy of the local and national trauma of the bombing that ended the period of Japanese militarism. A central theme of the movie is the need, at
The Chinese Nationalist Party (KMT) and the Taiwan People’s Party (TPP) on Friday used their legislative majority to push their version of a special defense budget bill to fund the purchase of US military equipment, with the combined spending capped at NT$780 billion (US$24.78 billion). The bill, which fell short of the Executive Yuan’s NT$1.25 trillion request, was passed by a 59-0 margin with 48 abstentions in the 113-seat legislature. KMT Chairwoman Cheng Li-wun (鄭麗文), who reportedly met with TPP Chairman Huang Kuo-chang (黃國昌) for a private meeting before holding a joint post-vote news conference, was said to have mobilized her
Before the Chinese Communist Party (CCP) and its People’s Liberation Army (PLA) can blockade, invade, and destroy the democracy on Taiwan, the CCP seeks to make the world an accomplice to Taiwan’s subjugation by harassing any government that confers any degree of marginal recognition, or defies the CCP’s “One China Principle” diktat that there is no free nation of Taiwan. For United States President Donald Trump’s upcoming May 14, 2026 visit to China, the CCP’s top wish has nothing to do with Trump’s ongoing dismantling of the CCP’s Axis of Evil. The CCP’s first demand is for Trump to cease US
RSS